Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

neurostatins

- PMLiVE

Nanoparticle-delivered RNA could offer potential therapy for neuroinflammation

The study demonstrated a new way to deliver RNA to the brain's immune cells

- PMLiVE

New report identifies key issues with NICE’s methods for evaluating Alzheimer’s drugs

Several disease-modifying treatments for use in Alzheimer's disease are at varying stages of development and regulatory approval

- PMLiVE

New £5m project launched to bring Alzheimer’s blood tests to the NHS

Blood tests for the condition could become available on the NHS within five years

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

- PMLiVE

UCL study finds certain ethnicities experience greater effect of dementia risk factors

Researchers analysed health data from nearly one million adults in England

- PMLiVE

Alzheimer’s Research UK awards Cardiff University researchers £387,000

The researchers will investigate how genes accelerate the development of Alzheimer’s disease

- PMLiVE

Researchers discover how neurons die in Alzheimer’s disease

The findings open up potential avenues to develop new treatments for the condition

- PMLiVE

MIT study finds drug candidate reduces inflammation in Alzheimer’s models

The candidate significantly reduced inflammation and improved cognitive functions

- PMLiVE

Alzheimer’s Research UK calls on party leaders to tackle dementia pressures

One in three people living with dementia in England never receive a formal diagnosis

- PMLiVE

Study reveals gut conditions could be early sign of Parkinson’s disease

Constipation, dysphagia and IBS could be potential biomarkers of the condition

- PMLiVE

Alzheimer’s Research UK awards £370,000 to University of Exeter researchers

The grants are part of a wider £3m funding announcement that aims to accelerate effective treatments for dementia

- PMLiVE

Quest Diagnostics launches Alzheimer’s blood test for US consumers

Alzheimer's disease is expected to affect around 14 million people in the US by 2060

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links